ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicNovel Immune Markers and Predictive Models for Diagnosis, Immunotherapy and Prognosis in Lung CancerView all 11 articles
A Novel 12-gene Immune Signature with KRT6B as a Hub Gene Predicts Prognosis and Therapeutic Targets in Lung Adenocarcinoma
Provisionally accepted
- 1Fujian Medical University Union Hospital, Fuzhou, China
- 2Shandong First Medical University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Lung adenocarcinoma (LUAD) exhibits high mortality and heterogeneity. While immune-related signatures show prognostic potential, robust models validated through both computational screening and experimental methods are lacking. Methods: Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) database and three Gene Expression Omnibus (GEO) cohorts (GSE3141, GSE30219, and GSE50081) were analyzed. A 12-gene immune-related prognostic signature was constructed using LASSO Cox regression. The model was subsequently validated using three independent external cohorts. Its prognostic performance was comprehensively assessed using time-dependent receiver operating characteristic (ROC) curves. Functional enrichment analyses (GO, KEGG, and GSEA), tumor microenvironment (TME) profiling (via CIBERSORT and ESTIMATE algorithms), and drug sensitivity analyses were conducted. Protein-protein interaction (PPI) network analysis identified KRT6B as a central hub gene. KRT6B expression and its functional role were further validated through tissue microarray immunohistochemistry (IHC), as well as in vitro and in vivo experiments. Results: We developed a prognostic model for LUAD based on 12 immune-related genes and derived a risk score via LASSO regression. High-risk patients exhibited significantly worse overall survival compared to low-risk patients in both the training set (TCGA) and the three independent validation cohorts (GSE3141, GSE30219, and GSE50081) (all P < 0.05). Time-dependent ROC analysis confirmed the model's predictive accuracy for 1-, 2-, and 3-year survival (AUC = 0.71–0.79). A nomogram incorporating the risk score and key clinical indicators further enhanced prognostic performance (AUC up to 0.76). PPI network analysis pinpointed KRT6B as a core hub gene within the signature. Subsequent experimental validation confirmed the overexpression of KRT6B in LUAD tumor cells and demonstrated its tumor-promoting functions both in vitro and in vivo. Conclusion: We established and validated an immune-related gene signature for prognostic prediction and identified KRT6B as a promising prognostic biomarker and a potential therapeutic target in LUAD.
Keywords: biomarker, Immune-related gene signature, Krt6b, Lung Adenocarcinoma, Prognostic model
Received: 27 Aug 2025; Accepted: 04 Feb 2026.
Copyright: © 2026 Gu, Wu, Jiang, Shi, Qi and Lai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jinhuo Lai
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.